Following the Fed rate cut and a change to capital rules, the US policymakers unveiled new plans to provide roughly $8 billion emergency funding bill to fight the coronavirus, as per the NBC news.
The bill, which passed by an overwhelming majority, provides $7.8 billion to fight the coronavirus and includes a mandatory funding authorization for $500 million over a 10-year period to be used toward a remote health care program.
The bill includes a provision that requires that funds are only used to fight the coronavirus and other infectious diseases as some Democrats feared that the Trump administration could raid the funding and use it for other unrelated purposes.
Trump had submitted a $2.5 billion request to Congress to combat the virus, but Democrats quickly said that that amount would be insufficient. Sen. Chuck Schumer, D-N.Y., responded with an $8.5 billion proposal. Schumer said Tuesday that he expected the final deal to be between $7 billion and $8 billion.
Trump said separately at an event in Washington on Tuesday morning, ‘It looks like they're going to give us $8.5 billion,’ and added, 'I think I should say, 'I'll take it.'
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.